Fellowship Program Pharmaceutical Industry - Rutgers Institute for Pharmaceutical ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Pharmaceutical Industry
42
43
44
45
Fellowship Program 46
47
48
49
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
ONTENTS Why Daiichi Sankyo?
• Company Overview ..............................................................................................................................................................3
• Core Values..........................................................................................................................................................................4
2
3
4
5
6
7
8
9
10
• A Message from Our U.S. President .....................................................................................................................................5 11
12
• The Fellowship Experience ...................................................................................................................................................6
13
• Why This Mid-Sized Company? ...........................................................................................................................................7 14
15
16
Recruiting Fellowships 17
• U.S. Medical Affairs Fellowship (2 Two-Year Positions)......................................................................................................8 18
19
• Global Medical Affairs Fellowship (2 Two-Year Positions) ................................................................................................13 20
• Global Business Development, Oncology Marketing & Market Research Fellowship (2 Two-Year Positions)....................16 21
22
• Pharmacoepidemiology (PE) Fellowship (1 Two-Year Position) .......................................................................................23 23
• Clinical Development (Global Oncology R&D) Fellowship (2 Two-Year Positions) ..........................................................27 24
25
• Quantitative Clinical Pharmacology (QCP) Fellowship (1 Two-Year Position) .................................................................31 26
• Global Regulatory Affairs – Oncology Fellowship (1 Two-Year Position) .........................................................................35 27
28
• Global Market Access & Pricing (GMA&P) Fellowship (2 Two-Year Positions) ................................................................38 29
• Precision Medicine Fellowship (1 Two-Year Position).......................................................................................................41 30
31
32
Daiichi Sankyo Past Fellow Experiences ................................................................................................................................44 33
34
35
Fellowship Alumni ..............................................................................................................................................................................45 36
37
38
Rutgers Pharmaceutical Industry Fellowship (RPIF) ................................................................................................46 39
• Program History .................................................................................................................................................................47 40
41
• Professional Development Series........................................................................................................................................48 42
• Key Program Features (FOSTER)........................................................................................................................................48 43
44
• Application Process and Eligibility ......................................................................................................................................49 45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
9
10
11
Daiichi Sankyo has a 100-year 12
13
history of innovation and 14
15
discovery, with a primary focus
16
17
18
on bringing forth novel therapies 19
20
in oncology and additional 21
22
focus on new horizon areas. 23
24
25
26
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical 27
therapies to improve standards of care and address diversified, unmet medical needs of 28
people globally by leveraging our world-class science and technology. With more than 29
100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo 30
HEADQUARTERS and its 15,000 employees around the world draw upon a rich legacy of innovation and 31
a robust pipeline of promising new medicines to help people. In addition to a strong 32
H U.S. Daiichi Sankyo, Inc.
portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision 33
211 Mt. Airy Road,
Basking Ridge, NJ 07920 to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” 34
35
Phone: +1 908 992 6400
H Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as
other research areas centered around rare diseases and immune disorders. For more 36
Global Daiichi Sankyo Co., Ltd.
information, please visit www.daiichisankyo.com. 37
3-5-1, Nihonbashi Honcho,
38
Chuo-ku, Tokyo, 103-8426 Japan
Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo Group and is focused on the 39
40
development of oncology therapies and specialty medicines. Daiichi Sankyo, Inc. medicines
REVENUE FY19 approved in the U.S. include therapies for metastatic breast cancer, tenosynovial giant
41
H U.S. 42
Global cell tumor, metastatic melanoma, hypertension, dyslipidemia, diabetes, thrombosis, stroke
43
$9.028 $1.499 risk reduction, acute coronary syndrome and IV iron therapy.
44
billion billion* 45
46
47
48
49
* This includes revenue generated by Daiichi Sankyo, Inc., and American Regent, Inc. Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
9
10
Daiichi Sankyo 11
12
Values & Commitments 13
14
15
Daiichi Sankyo’s values are the guiding principles that VATION: Our Imper 16
O ativ
direct decision-making. They speak to what is important INN e
17
18
to the organization and the individuals, along with what To take a global
perspective
19
20
patients, customers and employees can expect. To create
and respect
regional To foster
21
innovative values intellectual 22
medicines curiosity and 23
Innovation changing SOC* strategic insight 24
Pharmaceutical innovation and therapeutic advances have had a dramatic impact on the lives of
AC C O U TABILITY
25
millions of people the world over. Innovation is our passion as well as a fundamental requirement 26
in our ongoing pursuit to create innovative, world-class medicines. We encourage each employee 27
To demonstrate To provide
to share in the spirit of innovation. professionalism, the highest 28
respect for quality 29
N
Integrity others and
teamwork
medical
information 30
We are distinguished by integrity. We strive to do things right as well as do the right things to 31
ngth
improve the health and well-being of patients worldwide. 32
To provide
To be a stable supply 33
Accountability accountable
34
tr e
of top-quality
for achieving
Accountability is the cornerstone of our culture. It is at the intersection of research and patient our goals To be an
pharmaceutical 35
:O
rS
need that we find our greatest challenges and our most extraordinary opportunities. We products
ethical, 36
demonstrate our compassion for people, and we honor our commitments to all those who depend trusted and
ur
37
Ou
on us to provide innovative therapies to patients around the globe.
Cu respectful
: 38
partner
lt u TY 39
re R I
G 40
INTE 41
42
43
*SOC (Standard of Care): Universally applied best 44
treatment practice in today’s medical science 45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
“Daiichi Sankyo is a unique, global organization that has a rich 29
history of innovation, research and discovery. As our people 30
31
embrace challenges, we support them in seeking new opportunities 32
and growing their careers. Fellows thrive in the culture we have 33
34
built at Daiichi Sankyo and begin contributing to our mission, 35
to bring new, meaningful medicines to the world, from day one.” 36
37
38
Ken Keller, 39
40
President and CEO, Daiichi Sankyo, Inc. & American Regent, Inc. 41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
9
10
11
Promising New Compounds Professional Connections
12
13
More than 35 products currently in our Fellows are integrated into project teams which 14
pipeline in diverse therapeutic areas help expand their professional network 15
16
17
18
19
20
21
42 Fellowship Alumni Global Mid-size Company 22
23
Unique and valuable hands-on Provide products in over 20 countries and
24
experience for every fellow encompass 15,000 employees worldwide
25
26
27
28
29
30
31
32
33
Therapeutic Areas Leadership Potential 34
Fellows plan and execute strategy and tactics by leading 35
Areas of focus include: 36
oncology and specialty therapeutics projects, presentations and meetings cross-functionally
37
38
39
40
41
42
Track Record of Innovation
Diverse Career Opportunities
43
Heritage of scientific discovery spans 110 44
years from the discovery of epinephrine to the Fellows have crossed into different functional 45
development of the first statin and glitazone areas both during and after the program 46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
Why This Mid-Sized
6
7
8
Company? 9
10
11
12
At Daiichi Sankyo, Inc., our people are our greatest asset 13
14
and by investing in inclusion and diversity practices across the 15
organization we firmly believe we are able to bring the best medicines 16
to our patients. Our goal is to become a global pharmaceutical 17
18
leader by 2025. To do this, we’re developing a culture of belonging 19
in which we elevate all voices to enable all our colleagues to bring 20
their full selves to work. This way, we leverage the vast experiences, 21
perspectives and talent of our employees to meet our important 22
23
business goals and bring innovative medicines to our patients. 24
25
26
• Individualized experience aligned with fellows’ interests 27
28
• Broad support throughout the organization 29
30
• Close interactions with high-level positions and peers 31
32
• Many opportunities to lead, rotate and/or assist with 33
projects in various areas of the business to gain exposure 34
to different areas of the pharmaceutical industry 35
36
• Open and approachable leaders 37
38
• Comfortable and supportive work environment 39
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
U.S. Medical Affairs
9
10
11
Fellowship
12
13
14
15
• 1 Two-Year U.S. Medical Affairs Position 16
17
• 1 Two-Year U.S. Medical Affairs - 18
Medical Information & Education Position 19
20
The goal of the two-year U.S. Medical Affairs Fellowship Program is to provide real-world, 21
hands-on experience in oncology across traditional functional areas of a Medical Affairs 22
Department. Core functional areas of the U.S. Medical Affairs Department include Medical 23
Information & Education, Medical Research & Strategy, and Field Medical. There will 24
be two different U.S Medical Affairs fellowships available: U.S. Medical Affairs and U.S. 25
Medical Affairs — Medical Information & Education. Throughout their program, fellows will 26
gain a greater in-depth understanding of Medical Affairs as well as cross-functional 27
interdependencies within the pharmaceutical industry. 28
29
The first year of the U.S. Medical Affairs position is designed to be project-based as 30
opposed to rotational. The fellow will support the development of medical strategies, with 31
opportunities to obtain tactical experience with the Medical Information & Education team 32
as well as field-based opportunities to interact with key medical leaders in oncology. This 33
provides the fellow with the ability to learn across the various functional areas of Medical 34
Affairs. In the second year, the fellow will concentrate his or her time in a specific functional 35
area based on personal interest, experience, and the business needs of the Company. 36
37
The first year of the U.S. Medical Affairs – Medical Information & Education position will 38
be focused on projects within the Medical Information & Education group. This opportunity 39
will help the fellow to develop extensive skills in conducting literature searches, data 40
interpretation, and creating scientific content. Additionally, the fellow will gain significant 41
experience in medical review for promotional and non-promotional materials. In the second 42
year, the fellow will have the opportunity to work on projects across functional areas within 43
Medical Affairs to become exposed to a variety of new roles. 44
45
46
47
48
U.S. Medical Affairs Fellows 49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
U.S. Medical Affairs Fellowship Activities & Experiences 7
8
9
10
Responsibilities Interaction with 11
12
13
Responsibilities may include: (as they relate to U.S. Medical Affairs’ 14
daily activities and special projects): 15
- Creating, updating and reviewing fair and scientifically-balanced response documents
- Field Medical Affairs 16
to unsolicited medical inquiries
17
- Participating in dossier and testimony development - Health Economics and
18
Outcomes Research
- Serving as a scientific resource to the Product Material Review Team to evaluate 19
promotional materials - Pricing & Access 20
- Clinical Operations 21
- Strategically reviewing medical literature to identify educational gaps
22
- Assisting in coordination and planning of advisory board meetings - Marketing
23
- Working with vendors on medical slide development and review, as well as scientific - Sales Training 24
communication efforts and disseminating information internally - Clinical Development 25
26
- Reviewing publications in development to ensure manuscripts are scientifically accurate - Legal Affairs
27
- Assisting in strategic congress planning and coordination with key internal stakeholders - Public Affairs 28
on medical affairs activities 29
- Contributing to medical and scientific competitive intelligence monitoring and reporting 30
31
- Supporting medical training of the sales team and field medical team 32
- Collaborating with field medical teams to help convey critical insights back to the home office 33
- Supporting Investigator Initiated Review Committee as a scientific resource in the evaluation 34
of unsolicited research proposals 35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50
WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
U.S. Medical Affairs Fellowship Path Possibilities 6
7
8
U.S. MEDICAL AFFAIRS 9
10
U.S. MEDICAL MEDICAL INFORMATION 11
AFFAIRS & EDUCATION 12
13
14
15
16
17
18
19
20
FIRST YEAR IS PROJECT-BASED FIRST YEAR IS CONCENTRATED ON 21
ACROSS VARIOUS FUNCTIONAL AREAS: MEDICAL INFORMATION & EDUCATION 22
23
24
25
Medical Research & Strategy
26
27
SECOND YEAR IS PROJECT-BASED 28
ACROSS VARIOUS FUNCTIONAL AREAS: 29
30
Medical Information & Education
31
32
Medical Research & Strategy
33
34
35
Field Medical Affairs
36
37
Medical Information & Education
38
39
40
41
42
Field Medical Affairs
43
SECOND YEAR IS CONCENTRATED 44
WITHIN A FUNCTIONAL AREA OF INTEREST 45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
Current Fellow PERSPECTIVES
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
“Daiichi Sankyo has been a great “The fellowship program preceptors “As a first year fellow, I have “This fellowship has provided me 23
place to start my career in the come together to provide a thorough access to many unique with an in-depth understanding 24
pharmaceutical industry. As a and unique experience for each opportunities within medical of the different areas within 25
second year fellow, I’ve had fellow. Each of us is assigned information and education, as medical affairs. The longitudinal 26
the opportunity to work across different day-to-day preceptors well as experiences in all other project-based format has allowed 27
a number of different pipeline covering specific drugs and disease functions of medical affairs. me to integrate into medical 28
products and a variety of projects states, giving us our own domain to Additionally, the medical affairs research and strategy, medical 29
to help drive the development flourish in. Additionally, there is a fellows are considered valuable information and education, and 30
of U.S. strategy. I’ve also had strong panel of overarching leaders individuals who are capable of field medical while simultaneously 31
the chance to work with the that ensures each fellow has core handling many responsibilities providing opportunities to 32
other functional groups within experiences that are fundamental and are heavily invested in. collaborate cross-functionally. 33
Medical Affairs, including Medical for professional development. These unique opportunities The leadership team is committed 34
Information & Education and Fellows are also given opportunity to and the culture of mentorship to helping me achieve my goals 35
Field Medical to gain experiences grow outside of these responsibilities at Daiichi Sankyo are laying a and develop the skills I need to 36
in tactically executing based and functions to learn about and thick foundation on which I support a successful career in 37
on our strategic objectives. participate in other areas of interest. am confident I will be able to the pharmaceutical industry.” 38
The diverse experiences I’ve At the conclusion of this program, build a successful career on.” 39
Alex Huelsman, Pharm.D. 40
had thus far will make me a I will have a strong foundation in
Joseph Cheng, Pharm.D. First-Year Fellow, U.S. Medical Affairs 41
strong candidate upon medical affairs along with my own
First-Year Fellow, U.S. Medical Affairs University of Florida 42
completion of the fellowship” individual strengths and experiences.”
Rutgers University, 43
Haeyon Lee, Pharm.D. Samantha Breckenridge, Pharm.D. Ernest Mario School of Pharmacy
44
Second-Year Fellow, U.S. Medical Affairs Second-Year Fellow, U.S. Medical Affairs 45
University of North Carolina, University of Missouri - Kansas City, 46
Eshelman School of Pharmacy School of Pharmacy 47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
U.S. Medical 5
6
Affairs Leadership Fellowship Preceptor Testimonials & Insights 7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
“The best thing about the Rutgers
24
Fellowship is the way the fellows “The Medical Affairs Fellowship “The Medical Affairs Fellowship “A distinguishing characteristic 25
become an integral part of the Program is well established Program is dedicated to providing of our fellowship program is the 26
Daiichi Sankyo Medical Affairs and respected throughout an individualized experience for real-world educational experience 27
team. Working with dedicated the organization. We have an each fellow, which comes with that goes beyond observation. 28
and committed preceptors, the outstanding support system from full support from the leadership Fellows are immersed in the core 29
fellows quickly come up to speed the Medical Affairs Leadership team and preceptors. The program functional areas and gain a broad 30
on multiple products. Through Team as well as countless fellowship allows fellows to have various medical affairs perspective, butalso 31
their presentations and through alumni throughout the organization. experiences and opportunities a clear comprehension of roles, 32
their participation in Medical The leadership team oversees throughout medical affairs, while responsibilities and importance 33
Affairs activities, the Rutgers each fellow's development plan collaborating with other functional of cross-functional collaboration. 34
Fellows have the opportunity and is dedicated to their personal areas such as commercial, legal, Fellows are seen as active 35
to grow in responsibility and growth and progress. This coordinated and clinical development. Through contributors and are recognized as 36
leadership. The fellows soon involvement helps ensure each these experiences, the fellows team members. During the second 37
become valued, trusted members fellow has the support they need learn the skills necessary and year, acquired professional skills are 38
of an engaging scientific Medical to succeed throughout their build a professional network to honed, and continued confidence 39
Affairs community.” fellowship and into their careers.” establish a successful career.” is gained through an individualized 40
and concentrated experience.” 41
Howard Rutman, M.D., Kaley Lugo, Pharm.D., M.B.A. Preena Balani, Pharm.D. 42
M.B.A., F.A.C.C. Manager, Medical Information & Associate Director, U.S. Medical Affairs, Tamy Recchia, Pharm.D. 43
Vice President, U.S. Medical Affairs Education, Oncology | Preceptor Oncology | Preceptor Director, U.S. Medical Affairs, 44
Oncology | Preceptor 45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
9
10
11
12
Global Medical Affairs Fellowship
13
14
15
16
17
2 Two-Year Positions 18
19
20
The Global Medical Affairs (GMA) Team’s mission is to transform the scientific evidence of the broad and innovative Daiichi 21
Sankyo oncology portfolio to locally relevant clinical practice in all countries across the world. The GMA Team delivers 22
high quality scientific and medical information and publications needed to educate and support Health Care Professionals’ 23
treatment decisions, informing local and global treatment guidelines. GMA supports our Research and Development 24
colleagues by identifying evidence for potential new indications and sub-populations of interest. GMA supports access 25
submission efforts and educates Patient Organizations on the burden of the disease and its treatment options. 26
27
The goal of the Program is to introduce the fellows to the breadth and depth of different Global Medical Affairs activities 28
and to gain hands-on experience working on actual GMA deliverables. 29
30
In Year 1 (Rotational Year), fellows will gain broad exposure to different activities through rotation in four out of
31
six areas within GMA (approximately 3 months each). During this year the fellows will work under the guidance
32
of the respective Director to gain experience delivering against the Medical Affairs plan and participate in
33
strategic planning in:
34
• Publications • Medical Information & Education •Scientific Engagement 35
• Patient Advocacy • Evidence Generation •Clinical Operations 36
37
38
In Year 2 (Elective Year), fellows will focus on an area of their interest and gain a more in-depth experience 39
in a maximum of two areas (approximately 6 months in each of the two areas or 12 months in a single area). 40
41
The GMA Leadership Team will match the available areas for Year 1 and Year 2 fellows with their interest and with 42
an availability of a suitable project. This will allow the fellows to work on a project from its conception to the final 43
delivery with support from a GMA Director who is responsible for day-to-day operations of the respective area. 44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
Global Medical Affairs Fellowship Activities & Experiences 7
8
9
10
Responsibilities 11
12
13
The key responsibilities and projects vary depending on the GMA area and include: 14
Publications Scientific Engagement: Evidence Generation (Year 2): 15
16
- Preparing and submitting a - Planning, delivering and summarizing - Global project management 17
manuscript to a scientific journal outcomes of an external advisory - Real World Evidence 18
- Preparing and submitting an board (Medical Experts and/or Patient 19
- Assisting in building Global Brand
abstract to a global congress Advocacy Group Representatives) 20
Plans: Situation Analysis, Strategic
- Preparing a poster or slides for Imperatives and developing plans 21
an oral presentation for disclosure Patient Advocacy: for Medical Affairs activities 22
at a global congress 23
- Delivering on patient-oriented 24
activities Clinical Operations: 25
Medical Information & Education:
- Operational aspects of Expanded 26
- Generating Medical Information Evidence Generation (Year 1): Access Program, Daiichi-Sankyo- 27
standard response letters sponsored interventional and 28
- Assisting Global Medical Affairs
- Developing educational materials Team Lead with assessment non-interventional studies, Investigator 29
intended for internal training of evidence gaps and unmet Initiated Studies and External 30
- Preparing medical materials for medical needs Research Collaborations 31
presentation and display at global 32
- Planning activities to address
congresses at Daiichi-Sankyo booths 33
the identified gaps
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
Activities & Experiences (cont’d) Fellowship Leadership 7
8
9
10
Interactions Requirements 11
“The Global Medical Affairs 12
Fellowship Program is a unique 13
Global Medical Affairs interacts on a daily basis It is expected that fellows will have: experience that is easily 14
with multiple internal and external stakeholders.
- An interest in oncology through customizable based on the 15
participation in prior research projects, fellow’s interests. It is an 16
Key internal partner functions include:
internships, clinical rotations, etc. excellent way for the fellow 17
- Regional Medical Affairs
to gain hands-on experience 18
- Global Research and Development - A scientific curiosity and willingness to
in a pharmaceutical company 19
- Global Marketing navigate the complexities of oncology
during a relatively short time. 20
- Global Market Access and Pricing drug development from early clinical
It is also an investment by 21
- Global Clinical Safety and Pharmacovigilance stages to launch in different countries
Daiichi Sankyo to secure 22
- Legal around the world
future success. Our fellows will experience the breadth of 23
- Regulatory and Public Affairs - Ability to synthesize their knowledge and 24
Global Medical Affairs and will complete the fellowship as a
present in a clear and concise manner well-rounded Medical Affairs professional. They will ultimately 25
Key external partners include: when interacting on a daily basis with 26
be well-prepared to help oncology patients benefit from
- Global Key External Experts different GMA stakeholders the fellows 27
medications that improve their long-term outcomes and bring
- Healthcare Professionals (physicians, nurses, pharmacists) 28
them closer to cure.”
- Patient Advocacy Groups representing patients in 29
different countries and regions of the world Tomek Szczudlo 30
- Health Authorities (FDA, CHMP/ EMA, PMDA) Vice President, GMA Oncology Franchise Head, 31
- Medical Societies (ASCO, ESMO, ASH, EHA) Global Medical Affairs Oncology | Preceptor 32
33
During the participation in the program the fellows will be 34
encouraged and expected to participate in all interactions 35
with internal and external GMA stakeholders alongside 36
the other GMA Team members. 37
38
39
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
9
10
11
Global Business 12
13
Development,
14
15
16
Oncology Marketing
17
18
19
& Market Research
20
21
22
Fellowship
23
24
25
26
2 Two-Year Positions 27
28
29
30
The Global Business Development, Oncology Marketing & Market
31
Research Fellowship Program offers a unique opportunity for the 32
Pharm.D. or Pharm.D. / M.B.A. graduate to gain valuable industry 33
experience at a pharmaceutical company with a rich research history 34
and a promising future of growth. This two-year program is designed 35
to provide a comprehensive overview supporting compounds across 36
the full spectrum of product development, but with an emphasis on 37
oncology products, allowing hands-on opportunities, active coaching 38
and mentoring, as well as market research and business analytics 39
skill building. Our goal is to help provide the fellow with the tools 40
necessary for highly successful business development, marketing 41
and market research careers in the pharmaceutical industry. 42
43
The core focus of the program will be on Daiichi Sankyo, Inc.’s 44
internal pipeline for marketing and market research, and business 45
development opportunities in oncology. 46
47
48
Global Business Development, Oncology Marketing & Market Research Fellows 49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
9
10
Structure & Role of Global Commercial Fellowship 11
12
13
14
15
16
17
18
19
20
21
Global Business Development Oncology Marketing Market Research 22
23
Business Development is split up into two key functional Global Oncology Marketing helps to create the strategy Market Research is the link to physicians, patients 24
areas: search and evaluation of early opportunities for oncology products in the pipeline. This team partners and payers for brand teams and other important 25
and oncology transactions. This team’s key purpose with regions worldwide to ensure localization of the business partners. Market Research specifies the 26
is to screen and evaluate potential licensing, merger strategy and creation of brand identity. As a global information required to address business needs, 27
and acquisition opportunities and gather competitive team, responsibilities also include oversight of life-cycle designs methods for collecting information and 28
intelligence to help guide strategies for various strategies of its products across multiple tumor types. insights, analyzes the results and communicates 29
therapeutic areas. key findings and strategic recommendations. 30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
Global Commercial Fellowship Activities & Experiences 7
8
9
10
Responsibilities Career Development 11
12
13
Primary responsibilities, which will be developed throughout the fellowship, include: - New product, in-line and managed 14
care market research 15
- Participating in market research - Participating in national and
- Business Development product 16
activities in support of compounds international conferences
throughout all stages of product and market assessments 17
- Integrating core drug development 18
development (pre-clinical through launch)
and market inputs into commercial - Pharmaceutical business 19
- Designing and implementing qualitative/ value analysis analytics 20
quantitative primary market research
- Supporting product/market/company - Sales forecasting 21
- Interpreting patient and physician research evaluations in collaboration with 22
the Business Development team - Clinical trial assessments 23
- Assessing the strength of early-stage
pre-clinical and clinical trials - Monitoring and updating competitive - Pharmacology/therapeutics analysis 24
intelligence documents 25
- Validating forecast assumptions - New product and Commercial Marketing 26
and identifying key market drivers - Attending various medical and scientific 27
meetings/presentations to maintain - One-on-one preceptor mentoring
- Presenting research findings and 28
competitive intelligence for Daiichi Sankyo - Professional training opportunities
data to senior management 29
- Assisting brand teams in development and 30
- Analyzing and retrieving pivotal data
initiation of commercialization activities 31
through various secondary resources
and syndicated reports - Managing cross-functional projects 32
involving internal and external stakeholders 33
- Investigating and presenting scientific
34
information
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
Fellowship Path Possibilities 5
6
7
Join 8
9
Conduct initial scientific
Global Business Development
Prepare for national
partnership conferences
Execute projects
to gauge attractiveness
MOVE
NO
and technical evaluation Participate in financial
analysis of potential
10
Business (BD) Team Orientation and identify key of potential business
TO NEW
TEAM?
of opportunities
based on R&D and acquisition with 11
12
Dev opportunities opportunities commercial strategy finance department
13
A Team 14
YES
TH
15
A 16
P JUMP TO MARKET RESEARCH 17
OR BRAND TEAM 18
19
20
21
22
23
Join Research and Utilize market Develop target Support brand
24
MOVE 25
Oncology Oncology Marketing analyze product research insights TO NEW NO product profile for creation (e.g. brand 26
Team Orientation lifecycle management to develop brand Market Research name, logo, scientific
Marketing prospects and sales strategy
TEAM?
to forecast sales claim development) 27
28
Team 29
YES
B 30
ATH 31
P JUMP TO MARKET RESEARCH OR 32
BUSINESS DEVELOPMENT TEAM 33
34
35
36
37
38
39
Join Analyze syndicated Design and implement
primary market MOVE Research and Utilize market 40
Market Market Research
Team Orientation
reports to answer key
business questions for research to evaluate TO NEW
TEAM?
NO analyze life
cycle management
research insights to
forecast sales for
41
42
Research our oncology portfolio epidemiology and
patient journey prospects launching brands
43
Team 44
YES
45
C 46
ATH CROSS-FUNCTIONAL PROJECTS JUMP TO BRAND OR
47
P BUSINESS DEVELOPMENT TEAM 48
ALL FELLOWSHIPS ARE DIFFERENT BASED ON 49
FELLOW’S INTERESTS AND BUSINESS NEED Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
Current Fellow PERSPECTIVES 4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
“As a Fellow rotating in the Global “Supporting the Global Oncology “As a fellow in Global Oncology “Being a fellow with Global Business
21
Business Development department, Market Research team has Market Research, I’ve gained Development has given me a
22
I’ve had the opportunity to work on been a great experience. I’ve experience in market multitude of opportunities for
23
strategic projects early in my career. learned about planning/executing researching, forecasting, and growth. I’ve been able to work
24
I’ve attended virtual conferences qualitative market research competitive intelligence. I’ve with the Transactions team to
25
and partnering events with senior projects while also managing had the opportunity to work on evaluate and execute licensing 26
leadership team members, allowing several ongoing projects to support meaningful projects with senior and collaboration deals that 27
me to learn about novel assets, decision points for our pipeline leadership to gather actionable align with the company’s needs. 28
technologies, and mechanisms products. I’ve been fortunate to insights and drive strategic My preceptor and the leadership 29
being developed in the oncology work with and present to senior decision-making. From the start, team are supportive and willing 30
space. With the guidance of my leadership, while learning key the team has taken the time to facilitate my learning as I 31
preceptors, I’ve learned how to factors to consider when determining to learn my goals and ensure I continue through the fellowship 32
scientifically and commercially the commercial potential of assets. have the mentorship and skills program. The skills and experience 33
assess promising assets as well as Upon completion of the Fellowship, to excel in the industry upon I am gaining will lay a strong 34
develop and maintain relationships I will be in a great position to excel completion of my fellowship.” foundation for a successful future 35
with the respective companies. in the pharmaceutical industry.” in this career.” 36
Alberta Drake, Pharm.D., R.Ph.
These skills will help me be a Nikhil Dondapati, Pharm.D. 37
First-Year Fellow, Global Oncology Jill Desai, Pharm.D., R.Ph.
successful candidate in the industry Second-Year Fellow, Global Market Research Marketing 38
First-Year Fellow, Global Business
upon completion of my fellowship.” Rutgers University, Rutgers University, Development – Transactions 39
Rohan Chittella, Pharm.D. Ernest Mario School of Pharmacy Ernest Mario School of Pharmacy Rutgers University, 40
Ernest Mario School of Pharmacy 41
Second-Year Fellow, Global Business
Development – Search and Evaluation 42
Rutgers University, 43
Ernest Mario School of Pharmacy 44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
Global Business Development Leadership Team 7
8
9
10
11
“The Global Business Development group’s primary “A unique characteristic of being a fellow at a mid-sized 12
mission is to help create the future of Daiichi Sankyo pharmaceutical company like Daiichi Sankyo is the fact that 13
through the acquisition and licensing of external you won’t be an observer. You’ll be expected to rapidly 14
opportunities. Fellows in this program have the unique become a key contributor to the team and have the opportunity 15
opportunity to truly learn about the components that drive to impact the organization in meaningful ways. Fellows are 16
a pharmaceutical business, including: product assessment given a broad range of responsibilities and projects that are 17
and business development processes, key drivers in determined by actual business needs. The opportunities 18
decision making and how Commercial, R&D and Business created by this program enable the fellow to develop a 19
Development collaborate in building our product pipeline.” solid foundation in the pharmaceutical industry and build an 20
impressive list of completed projects and accomplishments.” 21
Jonathan York, M.D., M.B.A 22
Vice President, Global Business Development Mike Kostelansky, Ph.D. 23
Transactions Program Preceptor Director, Global Business Development 24
Oncology Transactions Program Preceptor 25
26
“At Daiichi Sankyo, we make it a priority to quickly integrate “Fellows may rotate to various departments to work with 27
the fellow to become an active member of the team. Through different mentors according to their own interests and business 28
the Business Development role in oncology, the fellow will needs. Rotating through Global Business Development, 29
have the opportunity to provide insight into new business Search and Evaluation gives fellows an opportunity to network 30
ventures and assess the scientific value of potential assets with and gain important insights from not only the internal 31
for acquisition that align with our commercial and scientific colleagues from different departments but also external 32
strategy to complement our pipeline. The fellow will gain partners including academic professors, CEOs of biotech 33
experience in managing projects and interacting with other companies, venture capitalists and investment bankers. 34
functions within a pharma company, which will prepare him or It will give the fellows a broad view of health the care industry 35
her extremely well for a future in the pharmaceutical industry.” in order to better apply science to business.” 36
37
Jeff Warmke, Ph.D. Fran Kern, Ph.D. 38
Senior Vice President, Global Business Development Executive Director, Global Business Development 39
Search and Evaluation Program Preceptor Search and Evaluation Program Preceptor
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
Global Oncology Marketing & Market Research Leadership Team 7
8
9
10
11
“Our Global Commercial Fellowship Program provides individuals “The Global Commercial Fellow will gain exposure to areas 12
with a variety of experiences that will give them an excellent within Business Development, Market Research and External 13
understanding of marketing, market research and planning. Scientific Affairs throughout the fellowship. Projects and 14
Our fellowship is designed to ensure that individuals have the mentorship here at Daiichi Sankyo will allow one to learn many 15
opportunity to make meaningful contributions to assessments facets of the pharma business including clinical development, 16
and analysis that are used by the company to make important the regulatory approval process, and what it takes to 17
strategic decisions and plans. The environment is one where successfully commercialize products in the rapidly evolving 18
our fellows are challenged and continually supported to ensure healthcare marketplace. We are happy to invest time and 19
that their personal and professional development is maximized. resources in the professional development of each fellow 20
Our program truly prepares them for a successful career.” based on his or her interests and needs of the organization.” 21
Matt Ricks, M.B.A. 22
Thierry Gruson, D.V.M., M.B.A. 23
Director, Market Research Oncology Commercial | Global Commercial
Vice President, Head of Global Oncology Marketing
Fellowship Managing Preceptor 24
25
26
“Daiichi Sankyo has a tradition of strong, challenging “The Rutgers Pharmaceutical Industry Fellowship program at 27
fellowship programs offered to outstanding Pharm.D. Daiichi Sankyo is the perfect conduit to thrive from the classroom 28
individuals who are inspired by our mission to bring into a real world setting. The commercial programs at DSI sets 29
innovative medicines to patients. Fellows have the unique fellows up to be successful in a highly cross functional environment 30
opportunity to apply their clinical knowledge and as fellows are able to rotate through key commercial roles while 31
experiences to key business questions impacting our collaborating closely with other functions such as clinical, regulatory, 32
organization to influence both our current and future medical affairs, and market access. We provide our fellows the tools 33
business. The program helps fellows develop a strong to be able to make highly strategic decisions while allowing them 34
foundation in the pharmaceutical industry while also to own projects to ensure they are confident in tactical execution. 35
advancing skills for personal and professional growth.” This program truly helps builds a strong foundation in the 36
pharmaceutical industry to set them up for success for the future.” 37
Janice Arnold
38
Global Brand Leader, Global Oncology Marketing Puja Patel, Pharm.D.
39
Director, Global Oncology Marketing
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
7
8
9
10
11
Pharmaco- 12
13
epidemiology (PE)
14
15
16
Fellowship
17
18
19
20
21
1 Two-Year Position 22
23
24
The Pharmacoepidemiology (PE) Fellowship Program is an initiative 25
between Daiichi Sankyo, Inc., the Ernest Mario School of Pharmacy 26
(EMSOP) at Rutgers University and the Rutgers Center for 27
28
Pharmacoepidemiology and Treatment Science. This is a two-year
29
fellowship training program in PE that provides education, real-world
30
and practical hands-on experience for Doctor of Pharmacy graduates
31
who want to become independent and successful practitioners in
32
the pharmaceutical drug development industry.
33
34
The aim of the PE Fellowship Program is to provide research skills
35
to conduct PE research for a career in the pharmaceutical industry.
36
Although all fellows are Rutgers employees and receive adjunct
37
academic appointments from the school, they will spend most of 38
their time at the corporate sponsor facilities. Pharmaceutical industry 39
preceptors will contribute to the professional development of the 40
fellow and to the capacity building in PE. 41
42
43
44
45
46
47
48
Pharmacoepidemiology Fellowship Team 49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
PE Fellowship Activities & Experiences 7
8
9
10
Responsibilities Interactions Requirements 11
12
13
The main responsibilities of In addition to pharmacoepidemiology It is expected that fellows will have: 14
pharmacoepidemiology fellows include: researchers and third party 15
investigators, it is expected that - Analytical, organization skills
- Assisting PE researchers in coordinating 16
fellows will interact with other - Oral and written communication skills 17
and planning collaborative meetings
R&D functions particularly: - Ability to work independently 18
with other functions and/or third parties
- Clinical Safety physicians and scientists and collaboratively with a team 19
- Searching, reviewing and critically
- High ethical behavior and ability 20
appraising the scientific literature - Clinical pharmacologists
to maintain human subjects 21
to answer PE research questions - Clinical researchers 22
confidentiality
- Participating in the scientific - Toxicologists 23
discussion to design PE studies - Evidence of successful presentations 24
- Data Management in professional meetings and
- Assisting PE researchers in the 25
- Biostatistics published manuscripts is a plus 26
statistical analysis of large databases
- Molecular Biologists - Previous experience in research is a plus 27
- Contributing in the preparation of 28
abstracts, posters, oral presentations - Regulatory Affairs
29
and manuscripts to communicate - Medical Affairs 30
results to scientific community 31
- Assisting PE researchers in preparing 32
responses for regulatory requests 33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
6
PE Fellowship Focus & Opportunity 7
8
9
10
Pharmacoepidemiology (PE) fellows will spend the first year working on a variety of projects that 11
will require different research methodologies in the areas of oncology, pain, cardiovascular and 12
others. In addition, they will attend PE courses at Rutgers University that will include introduction 13
to PE, study design and statistical analysis. During the first year, fellows will learn about the 14
infrastructure and organization of the pharmaceutical industry and will collaborate with core 15
functional areas from R&D. Fellows will have the opportunity to interact with preclinical and clinical 16
departments and learn first-hand how to identify and manage issues when developing new 17
pharmaceutical products. In addition, fellows will have the opportunity to learn pharmacovigilance 18
principles from highly skilled and experienced researchers. 19
20
In the second year, fellows will build upon their first year and will have the opportunity to learn 21
how to integrate information from different sources to make decisions. They will be exposed to 22
more sophisticated and advanced courses of PE. In addition, fellows will have the opportunity to 23
present results of their research in professional meetings and publish in peer-reviewed journals. 24
25
26
Over the course of the program, the PE fellow will have the opportunity to receive additional
27
training and mentorship from the Rutgers Center for Pharmacoepidemiology and Treatment
28
Science (PETS). PETS performs and fosters innovative, multi-disciplinary science related to the
29
use and outcomes of therapeutics and diagnostics in large populations, and seeks to advance
30
PE and related fields through world-class research and training.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50WHY DAIICHI U.S. MED. AFFAIRS GLOBAL MED. AFFAIRS GLOBAL COMMERCIAL PE CLINICAL DEV. QCP GLOBAL REG. AFFAIRS – GMA&P PRECISION MEDICINE PAST DAIICHI SANKYO
FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWSHIP ONC. FELLOWSHIP FELLOWSHIP FELLOWSHIP FELLOWS RPIF
SANKYO? FELLOWSHIP
1
2
3
4
5
Current Fellow PERSPECTIVES
6
PE Fellowship Leadership Team 7
8
9
10
11
“PE fellows will have the ability to use their pharmacy education 12
and extensive understanding of medications to contribute to the 13
understanding of the safety of Daiichi Sankyo products and their 14
potential impact in the “real world” setting. The PE fellows will gain 15
skills in the identification of safety-related issues, quantification of 16
risks using large databases, and establishing risk minimization 17
activities that will help them become integral members of the 18
epidemiology team.” 19
20
Vikram Dev 21
Vice President, Clinical Safety and Pharmacovigilance 22
“As the first pharmacoepidemiology “As a pharmacoepidemiology fellow, 23
fellow at Daiichi Sankyo, I have been I have the opportunity to collaborate 24
able to cultivate a unique fellowship cross-functionally with areas such 25
experience in collaboration with as regulatory, safety, and clinical on 26
“The PE fellowship at Daiichi Sankyo offers pharmacist fellows the 27
my preceptor. This fellowship has various products, both in development
ability to interact cross-functionally within the company on a variety 28
provided me with the opportunity to and mature. Even during these
of projects. The PE fellow will have the opportunity to learn PE 29
learn the fundamentals of PE through extraordinary times, the inclusive
methods and statistical analysis using large databases through 30
didactic courses while being able to culture fostered by Daiichi-Sankyo
courses taught at the university and their experiences in the 31
apply what I have learned to research shines through. Teamwork and
pharmaceutical industry. Over the course of two years, the PE 32
projects conducted at Daiichi collaboration are heavily emphasized
fellow will also gain experience in presenting data at scientific forums 33
Sankyo. This has allowed me to even with the majority of members
and interacting with other PE scientists from around the world.” 34
contribute meaningfully to the work working virtually. The fellowship is
35
I am involved in and has helped me deeply rewarding as my contributions, Maribel Salas
36
grow professionally as a pharmacist current and future, will have real-world Executive Director, Epidemiology and Clinical Safety and
Pharmacovigilance | Preceptor 37
working the pharmaceutical industry.” impacts and help bring lifesaving
38
medications to patients. ”
Mackenzie Henderson, 39
Pharm.D., R.Ph. Eric Wang, Pharm.D. 40
First-Year Fellow, Pharmacoepidemiology 41
Second-Year Fellow, Pharmacoepidemiology
Rutgers University, Ernest Mario School University of Missouri - Kansas City, 42
School of Pharmacy 43
of Pharmacy
44
45
46
47
48
49
Daiichi Sankyo Pharmaceutical Industry Fellowship Program 2021
50You can also read
